News2023-12-11T18:29:59+00:00

Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant

Company expects to enter clinic by 2023 and if approved, Delpor’s tizanidine implant will be the first minimally invasive, long-acting therapy for the maintenance of moderate to severe spasticity Expanded [...]

November 16th, 2021|

Delpor Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Once-Yearly Risperidone Implant

If approved, Delpor’s risperidone implant will be the first once-yearly schizophrenia maintenance therapy. BRISBANE, CA, April 22, 2021 — Delpor, Inc. (Delpor), a clinical-stage biopharmaceutical company that utilizes innovative technologies [...]

April 22nd, 2021|
Go to Top